WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP
Impact Factor 8.63
Volume 15, Issue 9, 436-439.
Review Article
ISSN 2277–7105

RECENT ADVANCES IN LIPID METABOLISM: MECHANISMS AND THERAPEUTIC IMPLICATIONS

Dr. Sahukar[1]*, Mr. Juber Khan[2], Mr. Samsad Khan[3], Mr. Rahul Khan[4]

[1]M. Pharma (Pharmacology), Ph. D, Associate Professor, Alwar Pharmacy College, Alwar, Rajasthan.

[2,3,4]M. Pharma (Pharmacology) Assistant Professor, Alwar Pharmacy College, Alwar, Rajasthan.

Article Received on 31 March 2026,
Article Revised on 21 April 2026,
Article Published on 01 May 2026

https://doi.org/10.5281/zenodo.19875233

***Corresponding Author**
Dr. Sahukar
M. Pharma (Pharmacology), Ph. D, Associate Professor, Alwar Pharmacy College, Alwar, Rajasthan.

How to cite this Article: Dr. Sahukar[1]*, Mr. Juber Khan[2], Mr. Samsad Khan[3], Mr. Rahul Khan[4] (2026). Recent Advances In Lipid Metabolism: Mechanisms and Therapeutic Implications. World Journal of Pharmaceutical Research, 15(9), 436–439.

ABSTRACT

Lipid metabolism encompasses the biochemical pathways responsible for the synthesis, breakdown, and interconversion of lipids in the body. Dysregulation of these pathways is implicated in various metabolic disorders, including obesity, diabetes, cardiovascular diseases, and cancer. This review examines the current understanding of lipid metabolic pathways, their regulatory mechanisms, and their role in disease pathogenesis. Additionally, it discusses emerging therapeutic strategies targeting lipid metabolism to mitigate disease progression.

KEYWORDS: Lipid metabolism, fatty acids, cholesterol, obesity, diabetes, therapeutic interventions.

1. INTRODUCTION

Lipids are essential biomolecules that serve as structural components of cell membranes, energy reservoirs, and signaling molecules. The metabolism of lipids involves complex enzymatic pathways that regulate the synthesis, degradation, and interconversion of various lipid species. Understanding these pathways is crucial, as their dysregulation can lead to the development of metabolic disorders such as obesity, type 2 diabetes, atherosclerosis, and cancer.

2. Overview of Lipid Metabolism

2.1 Fatty Acid Synthesis

Fatty acid synthesis occurs primarily in the liver and adipose tissue. The process begins with the conversion of acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase (ACC). Subsequently, fatty acid synthase (FAS) catalyzes the elongation of the carbon chain, leading to the formation of palmitate, the primary end product.

2.2 Beta-Oxidation

Fatty acids are oxidized in the mitochondria through β-oxidation, which sequentially removes two-carbon units from the fatty acid chain, producing acetyl-CoA, NADH, and $FADH_2$. These products enter the citric acid cycle and electron transport chain to generate ATP.

2.3 Cholesterol Metabolism

Cholesterol is synthesized from acetyl-CoA through a multi-step pathway, with 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) serving as the rate-limiting enzyme. Cholesterol is vital for membrane structure and serves as a precursor for steroid hormones and bile acids.

3. Regulation of Lipid Metabolism

3.1 Hormonal Regulation

-Insulin: Promotes fatty acid synthesis and inhibits lipolysis.

-Glucagon: Stimulates lipolysis and fatty acid oxidation.

- Epinephrine: Enhances lipolysis during stress responses.

3.2 Transcriptional Regulation

- Sterol Regulatory Element-Binding Proteins (SREBPs): Activate genes involved in lipid biosynthesis.
- Peroxisome Proliferator-Activated Receptors (PPARs): Regulate genes associated with fatty acid oxidation and energy metabolism.

3.3 Nutritional Influences

Dietary intake influences lipid metabolism. High-carbohydrate diets promote lipogenesis, while omega-3 fatty acids and polyunsaturated fats reduce triglyceride levels and modulate gene expression.

4. Lipid Metabolism in Disease

4.1 Obesity and Insulin Resistance

Excess lipid accumulation in adipose tissue leads to inflammation and insulin resistance. Lipotoxicity, caused by free fatty acids and ceramides, disrupts insulin signaling pathways and impairs glucose uptake.

4.2 Cardiovascular Disease

Elevated cholesterol and triglycerides contribute to atherosclerotic plaque formation. Oxidized low-density lipoprotein (LDL) promotes endothelial dysfunction and inflammation.

4.3 Cancer

Cancer cells exhibit altered lipid metabolism to support rapid proliferation. Increased lipid synthesis and uptake enhance membrane biogenesis and energy supply.

5. Therapeutic Interventions

5.1 Pharmacological Agents

-Statins: Inhibit HMG-CoA reductase to lower cholesterol.

-Fibrates: Activate PPARα to enhance fatty acid oxidation.

-Omega-3 Supplements: Reduce triglycerides and inflammation.

5.2 Dietary Modifications

-Balanced intake of omega-3 and omega-6 fatty acids.

-Reduction of saturated fats and trans fats.

-Increased fiber and plant sterols to improve lipid profiles.

5.3 Emerging Therapies

-Targeting lipid droplet proteins for cancer therapy.

-Gene editing approaches to modulate lipid metabolism enzymes.

- Personalized nutrition based on lipidomic profiles.

6. Recent Advances and Future Directions

Advancements in lipidomics and metabolic imaging have provided new insights into lipid metabolism at the cellular and systemic levels. The integration of multi-omics approaches, including genomics, proteomics, and metabolomics, is helping identify biomarkers for early disease detection and therapeutic monitoring.

Future research aims to unravel the complex interplay between lipid metabolism and other metabolic networks, focusing on targeted interventions to mitigate disease risk.

7. CONCLUSION

Lipid metabolism is a dynamic process essential for energy homeostasis and cellular function. Its dysregulation contributes to a spectrum of diseases, including obesity, diabetes, cardiovascular disorders, and cancer. Recent research has expanded our understanding of lipid metabolic pathways, regulatory mechanisms, and therapeutic interventions. Continued exploration in this field holds promise for developing more effective treatments and precision medicine approaches.

REFERENCES

1. Fahy E, Subramaniam S, Brown HA, et al. A comprehensive classification system for lipids. J. Lipid. Res., 2005; 46(5): 839-861.
2. Jump DB. Fatty acid regulation of hepatic lipid metabolism. Curr. Opin. Clin. Nutr. Metab., Care. 2011; 14(2): 115-120.
3. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest., 2002; 109(9): 1125-1131.
4. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. J. Clin. Invest., 2016; 126(1): 12-22.
5. Peeters, R. Lipid metabolism in B. cell biology. Molecular Oncology. 2024.
6. Ito, A. Lipid metabolism in myeloid cell function and chronic inflammation. Frontiers in Immunology. 2025.
7. Petrenko, V. Lipid metabolism around the body clocks. Frontiers in Medicine. 2023.
8. Lőrincz, H., Harangi, M. Lipid metabolism in obesity and diabetes. Metabolites. 2023.
9. Carli, F. Lipid metabolism in MASLD and MASH: From mechanism to therapy. Journal of Hepatology Reports. 2024.
10. Wang, Y. Lipid metabolism and tumor immunotherapy. Frontiers in Cell and Developmental Biology. 2023.